This study seeks to examine the effectiveness of NRX-1074 in the treatment of negative
symptoms and cognition in schizophrenia compared to other agents at the glycine site which
have demonstrated inconsistent results for negative symptoms. In addition to testing
efficacy, we will examine the time course of response of symptoms as well as any effects on
memory consolidation.
Phase:
Phase 2
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health
Collaborators:
Naurex, Inc Naurex, Inc, an affiliate of Allergan plc